Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Drops By 26.8%

Synaptogenix, Inc. (NASDAQ:SNPX) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 21,800 shares, a decrease of 26.8% from the February 13th total of 29,800 shares. Based on an average trading volume of 15,000 shares, the short-interest ratio is presently 1.5 days. Currently, 1.6% of the company’s stock are sold short.

Synaptogenix Stock Up 3.1 %

SNPX stock traded up $0.09 during midday trading on Monday, hitting $2.81. The company’s stock had a trading volume of 585 shares, compared to its average volume of 12,896. Synaptogenix has a twelve month low of $2.32 and a twelve month high of $6.22. The company’s fifty day moving average price is $3.12 and its 200 day moving average price is $3.08.

Hedge Funds Weigh In On Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC acquired a new stake in Synaptogenix, Inc. (NASDAQ:SNPX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.34% of the company’s stock.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.